Destiny Pharma – Landmark XF-73 Phase 2 data published in journal
Announces publication of XF-73 nasal gel Phase 2 data in leading…
24 March 2023/by Healthcare TeamSequana Medical announces additional patents for DSR® in China and the United States
Ghent, Belgium – 22 March 2023 – Sequana Medical NV (Euronext…
22 March 2023/by Healthcare TeamiOnctura Announces Publication Of Pioneering Research Describing The Unique Biological Features Of Roginolisib
Preclinical Data On Roginolisib, An Oral First-In-Class Non-ATP…
16 March 2023/by Healthcare TeamWe’d love to hear from you
For more information about optimum Strategic Communications, please get in touch
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
Destiny Pharma – Landmark XF-73 Phase 2 data published in journal
/in Client newsSequana Medical announces additional patents for DSR® in China and the United States
/in Client newsiOnctura Announces Publication Of Pioneering Research Describing The Unique Biological Features Of Roginolisib
/in Client newsLeucid Bio and Great Ormond Street Hospital enter commercial agreement at new gene therapy manufacturing centre
/in Client newsFive companies receive additional financial support through BioInnovation Institute’s Venture House program
/in Client news